Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385521 | 0.78 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL2464202 | 0.78 | PTGS2 (1.00) | PTGS2PTGS1 | |
| SCHEMBL6044707 | 0.77 | PTGS2 (0.64) | PTGS2PTGS1 | |
| SCHEMBL9537667 | 0.75 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL9537442 | 0.74 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL9535342 | 0.73 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL9535471 | 0.72 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL9538133 | 0.72 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL9537417 | 0.71 | PTGS2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL9535031 | 0.71 | PTGS2 (0.55) | PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1539142-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER S DISEASE | Pharmacia Corporation (US) | 2005-06-15 | — | — | EP | claimed |
| EP-1536863-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | Pharmacia Corporation (US) | 2005-06-08 | — | — | EP | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| EP-1463500-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2004-10-06 | — | — | EP | claimed |
| US-20040138296-A1 | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease | PHARMACIA CORPORATION | 2004-07-15 | — | — | US | claimed |
| EP-1406696-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | Pharmacia Corporation (US) | 2004-04-14 | — | — | EP | claimed |
| US-20040063697-A1 | Compositions of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event | PHARMACIA CORPORATION | 2004-04-01 | — | — | US | claimed |
| WO-2004014367-A2 | USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S DISEASE | PHARMACIA CORPORATION (US) | 2004-02-19 | — | — | WO | claimed |
| WO-2004004833-A1 | USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT | PHARMACIA CORPORATION (US) | 2004-01-15 | — | — | WO | claimed |
| US-20030211163-A1 | Combination antiviral therapy | PHARMACIA & UPJOHN COMPANY | 2003-11-13 | — | — | US | claimed |
| US-20030153801-A1 | Compositions of cyclooxygenase-2 selective inhibitors and radiation for inhibition or prevention of cardiovascular disease | PHARMACIA CORPORATION | 2003-08-14 | — | — | US | claimed |
| WO-2003059347-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | claimed |
| WO-2002096516-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | claimed |
| US-20090291883-A1 | COMBINATION OF AN IMMUNOSUPPRESSIVE AGENT AND NONSTEROIDAL ANTI -INFLAMMATORY DRUGS TO TREAT DISEASE | BOSTON MEDICAL CENTER CORPORATION (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2008008549-A2 | COMBINATION OF AN IMMUNOSUPPRESSIVE AGENT AND NONSTEROIDAL ANTI -INFLAMMATORY DRUGS TO TREAT NEOPLASIA | BOSTON MEDICAL CENTER CORPORATION (US) | 2008-01-17 | — | — | WO | disclosed |
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | STEPHENSON DIANE T | 2007-06-28 | — | — | US | disclosed |
| WO-2003059347-A1 | USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | disclosed |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PHARMACIA CORPORATION | 2003-01-16 | — | — | US | disclosed |
| WO-2002096516-A1 | USE OF COMPOSITIONS COMPRISING CYCLOOXYGENASE-2 SELECTIVE INHIBITORS IN COMBINATION WITH RADIATION FOR INHIBITION OR PREVENTION OF CARDIOVASCULAR DISEASE | PHARMACIA CORPORATION (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030211163-A1 | Combination antiviral therapy | EIF2AK2, ZC3HAV1, VHL | PTGS2 1846/4885PTGS1 1821/4885 |
| US-20030119895-A1 | Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20040063697-A1 | Compositions of cyclooxygenase-2 selective inhibitors and thrombolytic agents for the treatment or prevention of a vaso-occlusive event | PTGIS, PTGIR, PTGS2 | PTGS2 3/4885PTGS1 4/4885 |
| US-20030013739-A1 | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia | PTGS2, PTGES2, PTGS1 | PTGS2 1/4885PTGS1 3/4885 |
| US-20070149591-A1 | Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885 |
| US-20040138296-A1 | Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease | APP, BACE2, PTGS2 | PTGS2 3/4885PTGS1 9/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | PTGS2 1/4885PTGS1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.